Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Study Summary

This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).

Conditions

Solid Tumor

Interventions / Drugs

IDE397 Sacituzumab govitecan

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment169 participants

Primary Completion—

Lead SponsorIDEAYA Biosciences

Data Retrieved2026-04-11 04:16:36.812092+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.